AR and prostate carcinoma: The semi-synthetic 3rd generation taxane derivative cabazitaxel (Figure 5, 31) was able to inhibit LNCaP and PC-3 prostate cancer cell proliferation and suppress Hsp40, HOP, and AR in prostate cancer cells at very low doses (0.3 nM) [125].